Axel Dignaß
YOU?
Author Swipe
View article: Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease‐PODCAST Study
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease‐PODCAST Study Open
Background Crohn's disease (CD) and ulcerative colitis (UC) are progressive inflammatory bowel diseases that often result in bowel damage, imposing a significant burden on patients with insufficient disease control due to the limited effic…
View article: International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials Open
Background and Aims Intestinal ultrasound (IUS) is increasingly used to monitor treatment efficacy in inflammatory bowel disease (IBD) trials. However, standardized definitions for response, remission, and optimal assessment timing remain …
View article: Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis
Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis Open
Background/Objectives: Direct comparative data for infliximab and vedolizumab are limited due to lack of head-to-head trials. This systematic review and meta-analysis compared the efficacy and safety of infliximab and vedolizumab as intrav…
View article: Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s Disease
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s Disease Open
Guselkumab, a selective interleukin-23 (IL-23) inhibitor, has emerged as a promising biologic therapy for the management of patients with moderate-to-severe Crohn's disease (CD) and has been recently approved for its treatment. Unlike conv…
Inadequate Therapy Response on Advanced Therapy in Ulcerative Colitis Adult Patients: A Retrospective Analysis of German Health Claims Data Open
Background The treatment landscape for active ulcerative colitis is rapidly evolving and current real‐world evidence on response to advanced therapy is limited. This study aimed to determine indicators of inadequate therapeutic response am…
View article: Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial Open
INTRODUCTION: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) …
View article: DOP069 Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitis
DOP069 Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitis Open
Background Guselkumab (GUS) is a dual-acting IL-23p19 subunit inhibitor that potently neutralises interleukin 23 (IL-23) and binds to CD64, a receptor on cells that produce IL-23.1 The QUASAR Phase 2b/3 studies have demonstrated efficacy a…
P0041 Assessment of real-world effectiveness of risankizumab in patients with moderate-severe Crohn’s disease in a global setting Open
Background The primary treatment goals in Crohn’s disease (CD) are to control symptoms, such as abdominal pain and diarrhea, and induce long-term endoscopic remission. The biologic risankizumab (RZB) was approved in 2022 for the treatment …
View article: P0061 Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study
P0061 Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study Open
Background Guselkumab (GUS) is a selective dual-acting IL-23p19 subunit inhibitor that potently neutralises interleukin 23 (IL-23) and binds to CD64, a receptor on cells that produce IL-23.1 GUS is now approved in the United States for tre…
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis Open
Among the available interventions, owing to its favourable efficacy and safety profile, mirikizumab has a relevant role in the long-term treatment of UC.
View article: Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework
Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework Open
Longstanding disease control in Crohn's disease (CD) is challenging and requires understanding treatment efficacy and outcomes assessment. With multiple novel therapeutic options, rigorous evaluation of outcomes in randomized controlled tr…
View article: Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective Open
Background Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized controlled trials (RCTs) in ulcerative col…
View article: Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn’s Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn’s Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials Open
Background Endoscopic remission has emerged as an important treatment target in Crohn’s disease (CD) and has been associated with improvement in long-term outcomes. We examined the relationship between achievement of endoscopic remission a…
Evaluating Inadequate Therapy Response in Ulcerative Colitis Adult Patients: A Retrospective Analysis of German Health Claims Data on Advanced Therapy Initiation Open
Background The treatment landscape for active ulcerative colitis (UC) is rapidly evolving and current real-world evidence on response to advanced therapy is limited. This study aimed to determine indicators of inadequate therapeutic respon…
Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study Open
Background/Aims: Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-trea…
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme Open
Background and Aims Ulcerative colitis [UC], a chronic inflammatory bowel disease, may manifest with symptoms of increased stool frequency [SF], rectal bleeding [RB], bowel urgency [BU], abdominal pain [AP], and fatigue. Mirikizumab, an an…
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study Open
Background Crohn's disease and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by a progressive nature of the disease resulting in subsequent intestinal damage, limited efficacy of current treatments and subopti…
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study Open
Background Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative c…
View article: Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus Open
Background and Aims Pragmatic studies designed to test interventions in everyday clinical settings can successfully complement the evidence from registration and explanatory clinical trials. The European consensus project PRACTICE-IBD was …
COMPARATIVE EFFICACY AND SAFETY OF SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE AND ULCERATIVE COLITIS: AN INDIRECT COMPARISON FROM RANDOMIZED CONTROLLED TRIALS Open
BACKGROUND In a previous meta-analysis on randomized controlled trials (RCT) in patients with moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC), infliximab (IFX) showed better efficacy in the induction phase and comparabl…